Vaccine specialist Genocea Biosciences Inc (NASDAQ:GNCA) struck a research deal with Dana-Farber Cancer Institute and Harvard Medical School to study cancer immunology. Under the March 5 alliance, researchers will use Genocea Biosciences Inc (NASDAQ:GNCA)’s proprietary T cell antigen discovery platform to find antigens that correlate with an anti-tumor immune response in melanoma patients. Genocea Biosciences Inc (NASDAQ:GNCA) stock performance was 23.28% in last session and finished the day at $22.45. Traded volume was 131.58K shares in the last session and the average volume of the stock remained 179.51K shares.
ETC-1002, a novel agent in development by Esperion Therapeutics Inc (NASDAQ:ESPR), lowered LDL levels by nearly 43% in patients with type 2 diabetes and hypercholesterolemia, according to phase 2 study results. Esperion Therapeutics Inc (NASDAQ:ESPR) rose 5.58 percent to $17.40 Friday on volume of 160,479.00million shares. The intra-day range of the stock was $16.37 to $17.74. Esperion Therapeutics Inc (NASDAQ:ESPR) has a market capitalization of $267.22million.
Anacor Pharmaceuticals Inc (NASDAQ:ANAC) CEO David Perry sold 65,000 shares of the company’s stock in a transaction dated Wednesday, March 5th. Anacor Pharmaceuticals Inc (NASDAQ:ANAC)’s stock on Mar 7, 2014 reported a increase of 6.01% to the closing price of $21.16. Its fifty two weeks range is $3.50-$23.04. The total market capitalization recorded $862.18million. The overall volume in the last trading session was 481,323.00million shares. In its share capital, ANA has 40.59million outstanding shares.
Drug maker CEL-SCI Corporation (NYSEMKT:CVM) announced that its first U.S located clinical trial site has been commissioned to conduct its phase 3 tests on its cancer drug injection “Multikine* (Leukocyte Interleukin) which is designed to treat head and neck cancer. On Friday, shares of CEL-SCI Corporation (NYSEMKT:CVM) advanced 11.90% to close the day at $1.41. Company return on investment (ROI) is -253.80% and its monthly performance is recorded as 48.42%. CEL-SCI Corporation (NYSEMKT:CVM) quarterly revenue growth is 78.48%.